Kulkarni Samarth
Reporting-owner CIK 1682019 · 1 role
An officer, director, or 10% holder who reports personal trades under Section 16. Distinct from Investors — 13F institutional managers, a separate SEC namespace.
Roles & Tenure
| Company | Role | Scope | Start | End |
|---|---|---|---|---|
| CRSPCrispr Therapeutics Ag | CEOChief Executive Officer | Operator | — | — |
Tenure dates are extracted from filings and still being backfilled — a blank Start or End is unknown, not necessarily open-ended. Source: SEC Form 3/4/5 & 8-K Item 5.02.
Pay vs Performance
| FY | CEO comp | Actually paid | Co. TSR ($100→) | Peer TSR | vs peers |
|---|---|---|---|---|---|
| 2022 | $20.7M | $1.7M | $67-33.3% | $111+11.3% | -45 pts |
| 2023 | $12.3M | $24.8M | $103+2.8% | $115+15.4% | -13 pts |
| 2024 | $33.2M | $10.0M | $65-35.4% | $114+13.8% | -49 pts |
| 2025 | $7.7M | $22.0M | $34-65.8% | $120+19.9% | -86 pts |
SEC Pay-vs-Performance (Reg S-K Item 402(v)). TSR is the value of a $100 investment at the measurement-period start — a cumulative index — converted here to a true cumulative return ($100→$78 shows as −22%, a loss). “vs peers” = the company’s cumulative TSR minus its disclosed peer group’s, in percentage points. Compensation as reported by the issuer.
Operator Score
The Operator board →Kulkarni Samarth’s Operator Score is still being computed. The score ranks a leader by the peer-relative alpha they delivered while in the seat— the stock’s return over their tenure, minus what a matched basket of peers returned over the same window, annualized. It is a percentile within the company’s market-cap × sector cohort, not a raw return.
Two inputs aren’t ready yet: a multi-year price-history backfill (only ~40 trading days are loaded today) and verified tenure start/end dates (most are still blank). Once both land, this fills in automatically.
Method locked (δ=0.3, k=3, Layers 0–3at launch). No number is shown until it can be computed and cohort-ranked — we don’t estimate.